ClinicalTrials.gg
TerminatedNCT03394937Updated Jun 21, 2021

Safety of Intranodal ECI-006 in Melanoma Patients

A Phase 1 interventional study of ECI-006 in Melanoma, sponsored by eTheRNA immunotherapies. Terminated at 9 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-06-21.

Sponsored by eTheRNA immunotherapies (part of Valerio Therapeutics) · Phase 1, Interventional, and Treatment

Why this study was terminated
Expiry of study medication

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2017, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 158 studies in Melanoma with a site in Belgium — 15 open to participants now, 37 under way, 16 of them phase 3. Melanoma · Belgium.

Enrollment
128th of 146
21 · median 197
Started
2017
with 9 others
Phase 1
26 of 158
1 open now
Registered
91st of 158
by date

Among the 158 studies in Melanoma with a site in Belgium, this one is the 128th largest by enrollment of the 146 interventional ones that give a count, is one of 10 that started in 2017, is one of 26 in phase 1, and was the 91st registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

15 of the 158 studies in Melanoma with a site in Belgium are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Melanoma with a site in Belgium, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of cancer immunotherapy ECI-006 and to determine its ability to induce a measurable immune response against the tumor associated antigens.

In Cohort 1, ECI-006 will be administered 5 times by intranodal injection in melanoma patients after resection of their tumor.

In Cohort 2, ECI-006 will be administered 9 times by intranodal injection on top of standard of care anti PD1 in metastatic melanoma patients with stable disease after 3 to 12 months treatment.

ECI-006 activates key immunologically active cells to direct the immune system against the cancer. Expected potential risks for ECI-006 are non-serious and related to the local administration of the product. Hence, the therapy suggested here has the promise to offer considerable benefit to patients without any major risk.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria Cohort 1:

  1. Age greater than or equal to 18 years and less than or equal to 80 years.
  2. Patients must have proven primary malignant melanoma of skin which has been surgically removed (see exclusion criterion on patients with primary uveal melanoma or melanoma of the mucosae).
  3. Patients with American Joint Committee on Cancer (AJCC) Stage IIc, III or IV.
  4. Patients must have no evidence of disease as evidenced by a whole body 18F fluorodeoxyglucose (FDG) positron emission tomography [PET]/computed tomography [CT] scan to be done at maximum 2 weeks before Visit 2. To exclude the presence of tumor lesions in the brain magnetic resonance imaging (MRI) may be performed.
  5. Full recovery from all prior therapies. A maximum period of 12 weeks following major surgery, or any other major invasive procedure is allowed before start of the study medication; at least 4 weeks should be between major surgery and the start of the immunotherapy
  6. Female patients of should have a negative serum pregnancy test at Visit 1 (Screening) and should use an efficient method of from screening until the first menses after a 4 week period after the last dose of study medication.

Main exclusion criteria Cohort 1:

  1. Patients with primary uveal or mucosal melanoma.
  2. Patients who have received prior systemic therapy and/or active immunotherapy for melanoma, such as antigen loaded dendritic cells or chimeric antigen receptor (CAR) T cells, are excluded. Systemic treatment for melanoma that is more than 5 years ago and prior local treatment of primary and tumor lesions (e.g., surgical resection, isolated limb perfusion radiotherapy) are allowed.
  3. Patients with a history of disease such as, but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, rheumatoid arthritis or multiple sclerosis. Vitiligo is not an exclusion criterion
  4. Patients with serious intercurrent chronic or acute illness such as pulmonary [asthma or (COPD)] or cardiac ( [NYHA] class III or IV) or hepatic disease or other illness considered by the investigator to constitute an unwarranted high risk for drug treatment.
  5. Concurrent second other than non-melanoma skin cancer, or controlled superficial bladder cancer. In the event of prior malignancies treated surgically, the patient must be considered NED (no evidence of disease) for a minimum of 3 years prior to enrolment.
  6. Patients on therapy > 10 mg prednisone (or equivalent) or other agents such as azathioprine or cyclosporine A (but not limited to these) are excluded on the basis of potential immune suppression. Patients must have had 8 weeks of discontinuation of any steroid therapy exceeding > 10 mg prednisone (or equivalent) before first dose.

Main inclusion criteria Cohort 2:

  1. Histologically confirmed AJCC Stage III or Stage IV unresectable disease.
  2. Patient must be free of progression and have stable disease after at least 3 months but less than 12 months of immunotherapy (pembrolizumab, nivolumab or combination of nivolumab and ipilimumab). Patients with clinically stable disease can be either:

    1. Patients with stable disease as defined by RECIST1.1 criteria as assessed on 2 consecutive imagings, or
    2. Patients deemed unlikely to respond further to the standard of care immunotherapy by the investigator, after an initial partial response.
  3. Patient must continue with standard of care pembrolizumab or nivolumab during the study.
  4. by means of clinical examination, computed tomography (CT) or magnetic resonance imaging (MRI) according to the (RECIST) Version 1.1, defined as:

    • At least 1 tumor lesion that can be accurately and serially measured in at least 1 dimension, and for which the greatest diameter is ≥ 10 mm or at least one malignant lymph node for which the short axis is ≥ 15 mm as measured by contrast enhanced or spiral CT scan and/or
    • At least 1 superficial cutaneous melanoma lesion ≥ 10 mm as measured by calipers and/or
    • At least 1 subcutaneous melanoma ≥ 10 mm lesion and/or
    • Multiple superficial melanoma lesions which in aggregate have a total diameter of ≥ 10 mm

Main exclusion criteria Cohort 2:

  1. Patient who received radiotherapy within 4 weeks prior to the start of treatment with study medication.
  2. Patients with active . Patients with brain metastases are eligible if the brain metastases are deemed stable and if the patient is eligible to receive pembrolizumab as standard of care to treat his melanoma in the judgement of the investigator. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 8 weeks prior to study drug administration.
  3. Patients with primary uveal or mucosal melanoma.
  4. Patients that are deemed at risk for autoimmune flare up (e.g. patients that had an ongoing/recurrent irAE in the last 3 months), as determined by the investigator.
  5. Patients who have received prior treatment for advanced melanoma other than standard of care first-line immunotherapy (pembrolizumab, nivolumab or nivolumab/ipilimumab combination) and targeted therapy (encorafenib, dabrafenib and trametinib) for BRAF positive patients preceding standard of care immunotherapy..
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Cohort 1 600 µg ECI-006

    Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 600 µg ECI-006

    Biological: ECI-006

  • Experimental
    Cohort 1 1800 µg ECI-006

    Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 1800 µg ECI-006

    Biological: ECI-006

  • Experimental
    Cohort 2 1800 µg ECI-006

    Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 1800 µg ECI-006

    Biological: ECI-006

  • Experimental
    Cohort 2 3600 µg ECI-006

    Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 3600 µg ECI-006

    Biological: ECI-006

Interventions

  • BiologicalECI-006

    ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

    Types of toxicities, incidences and severity will be summarized by descriptive statistics

    Time frame: 24 weeks

Secondary outcomes

  1. Immune response associated with ECI-006 administration

    Antigen-specific T cell responses will be investigated at several time points

    Time frame: 24 weeks

07

Study locations

9 sites
  • 032-004_GZA Sint-Augustinus
    Antwerpen, Belgium
  • 032-002_UCL Brussels
    Brussel, Belgium
  • 032-003_AZ Maria Middelares
    Gent, Belgium
  • 032-001_University Hospital Brussel
    Jette, Belgium
  • Site 032-007_AZ Sint Maarten
    Mechelen, Belgium
  • 034-001_Hospital Clinic de Barcelona
    Barcelona, Spain
  • 034-002_MD Anderson Cancer Center
    Madrid, Spain
  • 034-003_Hospital Universitario Ramon y Cajal
    Madrid, Spain
  • 034-004_Clinica Universidad de Navarra
    Pamplona, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Dec 2020, 42 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2017
First posted
Jan 9, 2018
StartActual
Jun 27, 2017
Primary completionActual
Dec 31, 2020
CompletionActual
Jan 29, 2021
Last update
Jun 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03394937
Responsible party
Sponsor
First posted
Jan 9, 2018
Start date
Jun 27, 2017
Primary completion
Dec 31, 2020
Completion
Jan 29, 2021
Last update
Jun 21, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion